Wyeth Says Requested OTC NSAID Labeling May Confuse Consumers
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA-requested NSAID cardiovascular warning may not be adequately supported for ibuprofen, Wyeth says. Agency’s six month implementation deadline is biggest challenge, but “some clarifications of wording may be required” to prevent consumer confusion, Advil marketer adds.
You may also be interested in...
Celebrex, NSAID Labeling Must Be Updated Within Three Months, FDA Says
FDA's labeling template calls for Pfizer's Celebrex and other prescription NSAIDs to add "black box" warnings on cardiovascular and gastrointestinal risks. FDA is also requiring a warning on skin reactions. The agency issues a medication guide for all NSAIDs.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.